Market news

According to a Bloomberg report, Danish company Lundbeck has been working with advisers to explore a potential takeover of Xeris.

CHICAGO, September 09, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive clinical development strategy, including Cornerstone, its Phase 3 registrational study design, as well as the commercial opportunity for XP-8121, its investigational once-weekly s

CHICAGO, August 26, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company’s Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism.

Xeris Biopharma’s August 6, 2026 update showed second-quarter revenue rising to US$92.1 million while net loss widened to US$31.1 million, and the company tightened its full-year 2026 total revenue guidance to US$385 million–US$390 million. Alongside record quarterly revenue, Xeris highlighted strong Recorlev momentum, full retirement of its convertible notes, and progress toward a Phase III start for XP-8121, reshaping its operational profile. We’ll now examine how this tighter 2026 revenue...

Xeris Biopharma Holdings (XERS) is back in focus after reporting record second quarter revenue of $92.1 million and tightening its 2026 revenue outlook to a range of $385 million to $390 million. See our latest analysis for Xeris Biopharma Holdings. The latest record quarter and tighter 2026 revenue outlook have arrived after a strong run in Xeris Biopharma Holdings' stock, with a 33.49% 90 day share price return and a 292.92% three year total shareholder return, although the 1 day share...

Motley Fool Press Release.

Xeris Biopharma Holdings Inc (XERS) posts a 29% revenue surge to $92.1 million, driven by RECORLEV's 81% growth, and lifts full-year 2026 outlook.

CHICAGO, August 06, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026.

These small-cap biotechs offer core businesses that fund a much bigger opportunity.

CHICAGO, July 23, 2026--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results before the open of the U.S. financial markets on Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Comp

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.